These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 31128178)

  • 1. Insight into ponatinib resistance mechanisms in rhabdomyosarcoma caused by the mutations in FGFR4 tyrosine kinase using molecular modeling strategies.
    Wu C; Chen X; Chen D; Xia Q; Liu Z; Li F; Yan Y; Cai Y
    Int J Biol Macromol; 2019 Aug; 135():294-302. PubMed ID: 31128178
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting wild-type and mutationally activated FGFR4 in rhabdomyosarcoma with the inhibitor ponatinib (AP24534).
    Li SQ; Cheuk AT; Shern JF; Song YK; Hurd L; Liao H; Wei JS; Khan J
    PLoS One; 2013; 8(10):e76551. PubMed ID: 24124571
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Functional screening of FGFR4-driven tumorigenesis identifies PI3K/mTOR inhibition as a therapeutic strategy in rhabdomyosarcoma.
    McKinnon T; Venier R; Yohe M; Sindiri S; Gryder BE; Shern JF; Kabaroff L; Dickson B; Schleicher K; Chouinard-Pelletier G; Menezes S; Gupta A; Zhang X; Guha R; Ferrer M; Thomas CJ; Wei Y; Davani D; Guidos CJ; Khan J; Gladdy RA
    Oncogene; 2018 May; 37(20):2630-2644. PubMed ID: 29487419
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Theoretical studies on FGFR isoform selectivity of FGFR1/FGFR4 inhibitors by molecular dynamics simulations and free energy calculations.
    Fu W; Chen L; Wang Z; Kang Y; Wu C; Xia Q; Liu Z; Zhou J; Liang G; Cai Y
    Phys Chem Chem Phys; 2017 Feb; 19(5):3649-3659. PubMed ID: 28094372
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structural analysis of the human fibroblast growth factor receptor 4 kinase.
    Lesca E; Lammens A; Huber R; Augustin M
    J Mol Biol; 2014 Nov; 426(22):3744-3756. PubMed ID: 25219510
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The catalytic activity of Abl1 single and compound mutations: Implications for the mechanism of drug resistance mutations in chronic myeloid leukaemia.
    Georgoulia PS; Todde G; Bjelic S; Friedman R
    Biochim Biophys Acta Gen Subj; 2019 Apr; 1863(4):732-741. PubMed ID: 30684523
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular mechanisms of the anti-cancer drug, LY2874455, in overcoming the FGFR4 mutation-based resistance.
    Dehghanian F; Alavi S
    Sci Rep; 2021 Aug; 11(1):16593. PubMed ID: 34400727
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of covalent inhibitors that can overcome resistance to first-generation FGFR kinase inhibitors.
    Tan L; Wang J; Tanizaki J; Huang Z; Aref AR; Rusan M; Zhu SJ; Zhang Y; Ercan D; Liao RG; Capelletti M; Zhou W; Hur W; Kim N; Sim T; Gaudet S; Barbie DA; Yeh JR; Yun CH; Hammerman PS; Mohammadi M; Jänne PA; Gray NS
    Proc Natl Acad Sci U S A; 2014 Nov; 111(45):E4869-77. PubMed ID: 25349422
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of FGFR4-activating mutations in human rhabdomyosarcomas that promote metastasis in xenotransplanted models.
    Taylor JG; Cheuk AT; Tsang PS; Chung JY; Song YK; Desai K; Yu Y; Chen QR; Shah K; Youngblood V; Fang J; Kim SY; Yeung C; Helman LJ; Mendoza A; Ngo V; Staudt LM; Wei JS; Khanna C; Catchpoole D; Qualman SJ; Hewitt SM; Merlino G; Chanock SJ; Khan J
    J Clin Invest; 2009 Nov; 119(11):3395-407. PubMed ID: 19809159
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structural study of ponatinib in inhibiting SRC kinase.
    Guo M; Duan Y; Dai S; Li J; Chen X; Qu L; Chen Z; Wei H; Jiang L; Chen Y
    Biochem Biophys Res Commun; 2022 Apr; 598():15-19. PubMed ID: 35151199
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The N550K/H mutations in FGFR2 confer differential resistance to PD173074, dovitinib, and ponatinib ATP-competitive inhibitors.
    Byron SA; Chen H; Wortmann A; Loch D; Gartside MG; Dehkhoda F; Blais SP; Neubert TA; Mohammadi M; Pollock PM
    Neoplasia; 2013 Aug; 15(8):975-88. PubMed ID: 23908597
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Computational biophysical characterization of the effect of gatekeeper mutations on the binding of ponatinib to the FGFR kinase.
    Mahapatra S; Kar P
    Arch Biochem Biophys; 2024 Aug; 758():110070. PubMed ID: 38909834
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structural insights into FGFR kinase isoform selectivity: diverse binding modes of AZD4547 and ponatinib in complex with FGFR1 and FGFR4.
    Tucker JA; Klein T; Breed J; Breeze AL; Overman R; Phillips C; Norman RA
    Structure; 2014 Dec; 22(12):1764-1774. PubMed ID: 25465127
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of novel Ponatinib analogues for reducing KDR activity as potent FGFRs inhibitors.
    Liu Y; Peng X; Guan X; Lu D; Xi Y; Jin S; Chen H; Zeng L; Ai J; Geng M; Hu Y
    Eur J Med Chem; 2017 Jan; 126():122-132. PubMed ID: 27750146
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ponatinib may overcome resistance of FLT3-ITD harbouring additional point mutations, notably the previously refractory F691I mutation.
    Zirm E; Spies-Weisshart B; Heidel F; Schnetzke U; Böhmer FD; Hochhaus A; Fischer T; Scholl S
    Br J Haematol; 2012 May; 157(4):483-92. PubMed ID: 22409268
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systematic Analysis of Tyrosine Kinase Inhibitor Response to RET Gatekeeper Mutations in Thyroid Cancer.
    Meng S; Wu H; Wang J; Qiu Q
    Mol Inform; 2016 Oct; 35(10):495-505. PubMed ID: 27712045
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DFG-out mode of inhibition by an irreversible type-1 inhibitor capable of overcoming gate-keeper mutations in FGF receptors.
    Huang Z; Tan L; Wang H; Liu Y; Blais S; Deng J; Neubert TA; Gray NS; Li X; Mohammadi M
    ACS Chem Biol; 2015 Jan; 10(1):299-309. PubMed ID: 25317566
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structural mechanism of the Pan-BCR-ABL inhibitor ponatinib (AP24534): lessons for overcoming kinase inhibitor resistance.
    Zhou T; Commodore L; Huang WS; Wang Y; Thomas M; Keats J; Xu Q; Rivera VM; Shakespeare WC; Clackson T; Dalgarno DC; Zhu X
    Chem Biol Drug Des; 2011 Jan; 77(1):1-11. PubMed ID: 21118377
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structure guided design of potent and selective ponatinib-based hybrid inhibitors for RIPK1.
    Najjar M; Suebsuwong C; Ray SS; Thapa RJ; Maki JL; Nogusa S; Shah S; Saleh D; Gough PJ; Bertin J; Yuan J; Balachandran S; Cuny GD; Degterev A
    Cell Rep; 2015 Mar; 10(11):1850-60. PubMed ID: 25801024
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Atomistic insights into the lung cancer-associated L755P mutation in HER2 resistance to lapatinib: a molecular dynamics study.
    Yang B; Zhang H; Wang H
    J Mol Model; 2015 Feb; 21(2):24. PubMed ID: 25620423
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.